Benefits
Postmenopausal bone turnover markers — no citation on this page
One 6-month trial reported that at 8 mg lycopene/day postmenopausal women had increases in serum P1NP (bone formation marker) and directional reductions in β-CTx (bone resorption marker) vs placebo. That trial carries no citation on this page, so its design and figures cannot be checked against any source listed here, and P1NP and β-CTx are turnover markers rather than bone density or fracture outcomes. Mechanism: activates Wnt/β-catenin and ERK1/2 pathways, upregulates RUNX2/COL1A (osteoblast differentiation), downregulates RANKL (osteoclast activation). The bone evidence on this page carries no citation and is limited to turnover markers and one small density pilot, so lycopene should not be positioned as part of a bone treatment regimen.
Tomato sauce bone density pilot
A small pilot reported less bone density loss with lycopene-rich tomato sauce than in a control group. That pilot carries no citation on this page, its stated lycopene dose is an order of magnitude higher than the doses used elsewhere on this page and could not be verified, and a pilot this small cannot establish a bone effect.
Prostate marketing claims — not supported by randomized trials
Despite heavy marketing, the randomized evidence is weak. A meta-analysis of 6 randomized trials found no significant PSA change overall (WMD -0.60, 95% CI -2.01 to 0.81, PMID 33355018), and its title states plainly that lycopene does not affect prostate-specific antigen. A reduction appeared only in the subgroup with baseline PSA at or above 6.5 µg/L (WMD -3.74, 95% CI -5.15 to -2.32), which is an exploratory subgroup finding. Pooled trials also found no reduction in benign prostatic hyperplasia or in prostate cancer diagnoses, although those figures carry no citation on this page. Positive data come from observational studies of dietary intake, which cannot show that a supplement changes any outcome. Take-home: this is one of the few areas where the popular claim has been directly tested and did not hold up.
Cardiovascular markers — modest effect
Meta-analyses report modest reductions in systolic blood pressure and improvements in endothelial function, mainly in people with elevated baseline readings, but those analyses are not cited on this page. An umbrella review covering 20 lycopene health outcomes concluded that the quality of the vast majority of the evidence was low or very low (PMID 33131949). Effects on LDL oxidation and CRP markers are not established by anything cited here. Effects most apparent in those with elevated baseline cardiovascular risk. Whole-tomato dietary patterns (Mediterranean diet) outperform isolated lycopene supplementation, suggesting matrix matters.
Skin photoprotection
A meta-analysis of 21 intervention studies found that tomato or lycopene supplementation significantly reduced delta-a* (a redness measure of UV-induced erythema) and significantly increased minimal erythema dose, skin thickness and skin density (PMID 36606553). Neither a percentage reduction nor an SPF equivalent comes from that review, so figures of that kind commonly quoted for lycopene are not supported by it. Any effect is a small addition on top of topical sunscreen, never a replacement for it.
Antioxidant activity — strongest mechanistic story
Lycopene has the highest singlet oxygen quenching capacity among dietary carotenoids — about 2x β-carotene. Accumulates particularly in tissues with high oxidative stress (prostate, testis, adrenal, skin). Mechanism is well-established at the molecular level. Clinical translation to specific outcomes has been more variable than the mechanism would predict.
Eye health — observational only
Observational studies of dietary intake have reported associations between lycopene and eye health outcomes, but observational dietary data cannot show that a lycopene supplement changes any eye outcome. Unlike lutein and zeaxanthin (which preferentially accumulate in the macula), lycopene's role in eye health is less specifically targeted. Lutein/zeaxanthin remain the primary carotenoids for eye-specific applications. No intervention trial cited on this page measured any eye outcome.
Bioavailability — cooked tomato products win
Lycopene from cooked tomato products (paste, sauce, ketchup) is 2-3x more bioavailable than from raw tomatoes. Heat disrupts cell walls and converts trans-lycopene to bioavailable cis-isomers. Take with dietary fat (carotenoids are fat-soluble). For supplementation: choose products with verified lycopene content (often 5-15 mg per serving), not just 'tomato extract' without specification.
Mechanism of action
Singlet oxygen quenching (strongest carotenoid)
Lycopene has the highest singlet oxygen quenching capacity among dietary carotenoids — approximately 2x β-carotene. Singlet oxygen is a major reactive oxygen species in lipid peroxidation. Quenching mechanism is physical (energy transfer) rather than chemical, allowing lycopene to remain functional after multiple quenching cycles.
Tissue accumulation pattern
Most abundant carotenoid in human plasma; accumulates particularly in tissues with high oxidative load — prostate, testis, adrenal glands, skin, liver. Tissue accumulation is often used to explain the pattern of reported effects, but that link is a hypothesis rather than something demonstrated in trials. Cooking tomatoes converts trans-lycopene to bioavailable cis-isomers.
Bone metabolism modulation
Lycopene activates Wnt/β-catenin and ERK1/2 signaling pathways, upregulating osteoblast differentiation markers RUNX2 and COL1A. Concurrently downregulates RANKL signaling, reducing osteoclast activation. Net effect in laboratory models: tilts bone turnover balance toward formation over resorption. This is a preclinical mechanism, not a demonstrated human bone outcome.
Lipid metabolism and cardiovascular pathways
Lycopene reduces LDL susceptibility to oxidation, modulates endothelial nitric oxide signaling, and modestly reduces cholesterol synthesis via HMG-CoA reductase modulation. Antioxidant effect within lipid bilayer is mechanism for cardiovascular markers.
Skin photoprotection
Lycopene accumulates in skin (particularly stratum corneum) and reduces UV-induced erythema measures in intervention trials, although no SPF equivalent has been established for it. Mechanism: direct ROS quenching plus modulation of MMP-1 (matrix metalloproteinase) expression that drives photoaging.
Clinical trials
176 postmenopausal Indian women randomized to 8 mg LycoRed lycopene/day × 6 months vs placebo.
176 postmenopausal Indian women
176 postmenopausal Indian women randomized to 8 mg LycoRed lycopene/day × 6 months vs placebo. Significant increase in serum P1NP (bone formation marker) and directional reduction in β-CTx (bone resorption marker). Indicates favorable shift in bone turnover balance. Industry-funded, and this trial carries no citation on this page, so its design, sample and results cannot be verified from any source listed here. P1NP and β-CTx are bone turnover markers, not bone density or fracture outcomes.
Pilot clinical trial in 39 postmenopausal women using 150 mg lycopene/day from tomato sauce × 3 months.
39 postmenopausal women
Pilot clinical trial in 39 postmenopausal women using 150 mg lycopene/day from tomato sauce × 3 months, although that stated dose is an order of magnitude higher than the doses used elsewhere on this page and could not be verified against any source. This pilot carries no citation on this page, so its figures cannot be checked. The reported result was less bone density loss than in the control group, and a pilot this small cannot establish a bone effect.
Evidence review and pooled analysis: 3 clinical trials (n=154 total) of lycopene for prostate cancer prevention.
3 clinical trials pooled
Evidence review and pooled analysis: 3 clinical trials (n=154 total) of lycopene in men. There was no statistical difference in PSA levels between lycopene and control groups, and the trials were at high or unclear risk of bias. The review concluded that the evidence was insufficient either to support or to refute an effect. This pooled analysis carries no citation on this page, so none of its figures can be checked against the sources listed.
Evidence review of 8 clinical trials evaluating lycopene for BPH and prostate cancer.
8 clinical trials pooled
Evidence review of 8 clinical trials evaluating lycopene for BPH and prostate cancer. The pooled analysis reported no significant effect on either outcome (RR 0.95 and RR 0.92), with a PSA reduction only in men already diagnosed. This review carries no citation on this page, so none of these figures can be checked against the sources listed, and nothing here supports using lycopene to manage or prevent any disease.
Pooled analysis of 6 clinical trials evaluating lycopene effect on PSA in non-metastatic prostate cancer.
6 clinical trials pooled
Pooled analysis of 6 clinical trials evaluating lycopene effect on PSA in non-metastatic prostate cancer. Overall: no significant PSA reduction (WMD -0.60, 95% CI -2.01 to 0.81). Subgroup analysis: significant reduction in patients with baseline PSA ≥6.5 µg/L (WMD -3.74). The overall result was null. The subgroup result is exploratory and does not establish a benefit, and the paper's own title states that lycopene does not affect prostate-specific antigen (PMID 33355018).